Skip to Main Content

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)

Conditions

Diabetes Mellitus - Type 1

Phase II

What is the purpose of this trial?

The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.

  • Trial with
    National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
  • Start Date
    11/26/2018
  • End Date
    08/31/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000023905